{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407186940
| IUPAC_name = 6,8-Difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
| image = Fleroxacin.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|fleroxacin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 79660-72-3
| ATC_prefix = J01
| ATC_suffix = MA08
| PubChem = 3357
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB04576
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = N804LDH51K
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01716
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 6273
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 3240
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H18F3N3O3/c1-21-4-6-22(7-5-21)15-12(19)8-10-14(13(15)20)23(3-2-18)9-11(16(10)24)17(25)26/h8-9H,2-7H2,1H3,(H,25,26)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = XBJBPGROQZJDOJ-UHFFFAOYSA-N


<!--Chemical data-->
| C=17 | H=18 | F=3 | N=3 | O=3 
| molecular_weight = 369.34 g/mol
| smiles = CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F 
}}

'''Fleroxacin''' is a [[quinolone antibiotic]].<ref>{{Cite journal  | last1 = Rubinstein | first1 = E. | title = History of quinolones and their side effects. | journal = Chemotherapy | volume = 47  | issue =Suppl 3  | pages = 3–8; discussion 44–8 | year = 2001 | pmid = 11549783 | doi=10.1159/000057838}}</ref> It is sold under the brand names '''Quinodis''' and '''Megalocin'''.

== Mechanism of action ==
Fleroxacin is a bactericidal drug that inhibits bacterial [[DNA gyrase]] and [[topoisomerase IV]]. Like other quinolones and fluoroquinolones the compound eradicates bacteria by interfering with DNA replication (bacterial [[DNA replication]], [[DNA transcription|transcription]], [[DNA repair|repair]] and [[Genetic recombination|recombination]]).<ref name="pmid15857125">{{cite journal |vauthors=Asahina Y, Iwase K, Iinuma F, Hosaka M, Ishizaki T |title=Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin |journal=Journal of Medicinal Chemistry |volume=48 |issue=9 |pages=3194–202 | date=May 2005 |pmid=15857125 |doi=10.1021/jm0402061 |url=https://dx.doi.org/10.1021/jm0402061 |accessdate=2014-09-26}}</ref><ref name="pmid8388200">{{cite journal |vauthors=Yoshida H, Nakamura M, Bogaki M, Ito H, Kojima T, Hattori H, Nakamura S |title=Mechanism of action of quinolones against Escherichia coli DNA gyrase |journal=Antimicrobial Agents and Chemotherapy |volume=37 |issue=4 |pages=839–45 | date=April 1993 |pmid=8388200 |pmc=187778 |doi= 10.1128/aac.37.4.839|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=8388200 |accessdate=2014-09-26}}</ref><ref name="pmid3000292">{{cite journal |vauthors=Wolfson JS, Hooper DC |title=The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro |journal=Antimicrobial Agents and Chemotherapy |volume=28 |issue=4 |pages=581–6 | date=October 1985 |pmid=3000292 |pmc=180310 |doi= 10.1128/aac.28.4.581|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=3000292 |accessdate=2014-09-26}}</ref>
Fleroxacin is active against many Gram-positive and Gram-negative bacteria. It is especially active against [[Shigella|Shigella species.]], [[Salmonella|Salmonella sp.]], [[Escherichia coli]], [[Branhamella catarrhalis]], [[Haemophilus influenzae]], [[Neisseria gonorrhoeae]], [[Yersinia enterocolitica]], [[Serratia marcescens]], [[Staphylococcus aureus]], [[Pseudomonas aeruginosa]].<ref name="pmid3085584">{{cite journal |vauthors=Chin NX, Brittain DC, Neu HC |title=In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone |journal=Antimicrobial Agents and Chemotherapy |volume=29 |issue=4 |pages=675–80 | date=April 1986 |pmid=3085584 |pmc=180465 |doi= 10.1128/aac.29.4.675|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=3085584 |accessdate=2014-09-26}}</ref><ref name="pmid2942103">{{cite journal |vauthors=Hirai K, Aoyama H, Hosaka M, Oomori Y, Niwata Y, Suzue S, Irikura T |title=In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative |journal=Antimicrobial Agents and Chemotherapy |volume=29 |issue=6 |pages=1059–66 | date=June 1986 |pmid=2942103 |pmc=180500 |doi= 10.1128/aac.29.6.1059|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=2942103 |accessdate=2014-09-26}}</ref>

== Pharmacokinetics ==
After [[oral administration]] fleroxacin is rapidly and well absorbed from the [[gastrointestinal tract]] and shows a good [[bioavailability]]. The [[antibiotic]] is widely distributed throughout the body and in the different [[biological tissues]]. In many biologic specimens the levels of fleroxacin are similar to those in plasma, but in [[bile]], nasal secretions, [[seminal fluid]], [[lung]], bronchial mucosa, and [[ovaries]], the drug concentrations are 2-3 times higher than those in plasma.<ref name="pmid8452186">{{cite journal |vauthors=Weidekamm E, Portmann R |title=Penetration of fleroxacin into body tissues and fluids |journal=Am. J. Med. |volume=94 |issue=3A |pages=75S–80S | date=March 1993 |pmid=8452186 |doi= |url= }}<!--|accessdate=2014-09-26--></ref>
The serum [[elimination half-life]], in subjects with normal renal function, is relatively long (9–12 hours), which permits once-daily dosing.
Approximately the [[Urine|urinary excretion]] is 38% of an orally administered dose within 48 h, and in urine is possible detect 8.6% of the N-demethyl metabolite and 4.4% of the N-oxide metabolite. Fleroxacin can penetrate into [[milk]] of nursing women. As quinolones are known to induce [[arthropathy]] in juvenile animals, administration of the drug to [[breast-feeding]] women cannot be allowed.<ref name="pmid8452360">{{cite journal |vauthors=Dan M, Weidekamm E, Sagiv R, Portmann R, Zakut H |title=Penetration of fleroxacin into breast milk and pharmacokinetics in lactating women |journal=Antimicrobial Agents and Chemotherapy |volume=37 |issue=2 |pages=293–6 | date=February 1993 |pmid=8452360 |pmc=187655 |doi= 10.1128/aac.37.2.293|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=8452360 |accessdate=2014-09-26}}</ref>

==Medical uses==
Fleroxacin is effective in the treatment of a wide variety of infections, particularly uncomplicated cystitis in women, acute uncomplicated pyelonephritis, [[gonorrhea]], bacterial enteritis, traveler's diarrhea, [[respiratory tract infections]] ( including exacerbation of chronic bronchitis).<ref name="pmid8861529">{{cite journal |author=Naber KG |title=Fleroxacin overview |journal=Chemotherapy |volume=42 Suppl 1 |issue= |pages=1–9 | date=March 1996 |pmid=8861529 |doi= 10.1159/000239485|url= }}<!--|accessdate=2014-09-26--></ref><ref name="pmid7601015">{{cite journal |vauthors=Balfour JA, Todd PA, Peters DH |title=Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections |journal=Drugs |volume=49 |issue=5 |pages=794–850 | date=May 1995 |pmid=7601015 |doi= 10.2165/00003495-199549050-00010|url= }}<!--|accessdate=2014-09-26--></ref>

== Adverse effects ==
In treated patients the most common adverse reactions are gastrointestinal, including [[dyspepsia]], [[nausea]], [[vomiting]], [[flatulence]], [[abdominal pain]], [[diarrhea]] and sometimes [[constipation]].
Also common disorders affecting the [[skin]] ([[itching]], [[urticaria]], [[rash]], [[phototoxicity]] and [[photosensitivity]])<ref name="pmid8689769">{{cite journal |vauthors=Kimura M, Kawada A, Kobayashi T, Hiruma M, Ishibashi A |title=Photosensitivity induced by fleroxacin |journal=Clin. Exp. Dermatol. |volume=21 |issue=1 |pages=46–7 | date=January 1996 |pmid=8689769 |doi= 10.1046/j.1365-2230.1996.d01-158.x|url= }}<!--|accessdate=2014-09-26--></ref> and [[central nervous system]] ([[dizziness]], [[headache]], [[tremor]], [[paresthesia]], [[Dysgeusia|impaired sense of taste]] and smell), psychiatric disorders (alteration of the [[sleep-wake cycle]] state of [[anxiety]], [[Depression (mood)|depression]], [[hallucinations]] and [[nightmares]]).<ref name="pmid2511802">{{cite journal |vauthors=Bowie WR, Willetts V, Jewesson PJ |title=Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin |journal=Antimicrob. Agents Chemother. |volume=33 |issue=10 |pages=1778–82 | date=October 1989 |pmid=2511802 |pmc=172754 |doi= 10.1128/aac.33.10.1778|url=http://aac.asm.org/cgi/pmidlookup?view=long&pmid=2511802 |accessdate=2014-09-26}}</ref><ref name="pmid8452181">{{cite journal |author=Geddes AM |title=Safety of fleroxacin in clinical trials |journal=Am. J. Med. |volume=94 |issue=3A |pages=201S–203S | date=March 1993 |pmid=8452181 |doi= |url= }}<!--|accessdate=2014-09-26--></ref>
Fleroxacin and other fluoroquinolones, are known to trigger [[seizures]] or lower the [[seizure threshold]], due to their inhibitory activity on [[GABA receptor]] binding. The antibiotic should not be administered to patients with [[epilepsy]] or a personal history of previous convulsive attacks as may promote the onset of these disorders.<ref name="pmid2173611">{{cite journal |vauthors=Taga F, Kobayashi F, Saito S, Ooie T, Kawahara F, Uchida H, Shimada J, Hori S, Sakai O |title=Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals |journal=Arzneimittel-Forschung |volume=40 |issue=8 |pages=900–4 | date=August 1990 |pmid=2173611 |doi= |url= }}<!--|accessdate=2014-09-26--></ref><ref name="pmid10078039">{{cite journal |vauthors=Kimura M, Fujiyama J, Nagai A, Hirayama M, Kuriyama M |title=[Encephalopathy induced by fleroxacin in a patient with Machado-Joseph disease] |language=Japanese |journal=Rinshō Shinkeigaku = Clinical Neurology |volume=38 |issue=9 |pages=846–8 | date=September 1998 |pmid=10078039 |doi= |url= }}<!--|accessdate=2014-09-26--></ref>

== Contraindications ==
Fleroxacin is contraindicated in patients with a history of [[hypersensitivity]] to the substance or any other member of the quinolone class, or any component of the medicine. Fleroxacin, like other [[fluoroquinolones]], can cause degenerative changes in weightbearing joints of young animals. The antibiotic should only be used in children when the expected benefits are outweigh the risks.

==References==
{{reflist}}

{{QuinoloneAntiBiotics}}

[[Category:Piperazines]]
[[Category:Fluoroquinolone antibiotics]]